Literature DB >> 18342172

Saturation prostate biopsy in high risk patients after multiple previous negative biopsies.

Kobi Stav1, Dan Leibovici, Judith Sandbank, Arie Lindner, Amnon Zisman.   

Abstract

OBJECTIVES: To evaluate the diagnostic value of saturation prostate biopsy in patients with prostate-specific antigen (PSA) greater than 10 ng/mL, PSA velocity greater than 0.75 ng/mL/year, free PSA ratio less than 0.2, and at least 3 sets of negative biopsy specimens.
METHODS: Twenty-seven patients underwent the procedure with the use of a transrectal approach under general or regional anesthesia. A systematic coverage of the peripheral zone was accomplished by maintaining a fixed distance between punctures (5 mm). In addition, multiple cores were obtained from the transition zone bilaterally, bladder neck, and midline according to a strict preplanned template.
RESULTS: The mean number of cores obtained per patient was 61.7 +/- 9.5 (range 41 to 76). Average PSA was 19.4 +/- 8.5 ng/mL (range 10.1 to 49). Prostate cancer (Gleason score 3+3) was found in 3 patients (11.1%). All 3 patients who received a diagnosis of cancer had minimal disease affecting less than 1% of a single core sampled from the peripheral zone. Two patients were designated for watchful waiting and 1 patient chose radical prostatectomy. His pathologic specimen contained carcinoma of prostate (Gleason 3+3) in less than 1% of the total prostate volume. All patients were discharged within 24 hours after the procedure. Asymptomatic bacteremia was documented in 1 patient. Two patients had epididymitis develop and were treated conservatively.
CONCLUSIONS: According to our findings, saturation prostate biopsy has low diagnostic yield in patients who previously had at least 3 sets of negative traditional biopsy specimens. In all the cases, that prostate cancer was found, it had histologic features consistent with biologically insignificant disease.

Entities:  

Mesh:

Year:  2008        PMID: 18342172     DOI: 10.1016/j.urology.2007.11.007

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  7 in total

1.  Watchful waiting and active surveillance approach in patients with low risk localized prostatic cancer: an experience of out-patients clinic with 12-year follow-up.

Authors:  Sergey Kravchick; Ronit Peled; Shmuel Cytron
Journal:  Pathol Oncol Res       Date:  2011-06-08       Impact factor: 3.201

2.  [18F]-2'-Fluoro-5-methyl-1-beta-D-arabinofuranosyluracil (18F-FMAU) in prostate cancer: initial preclinical observations.

Authors:  Hossein Jadvar; Li-Peng Yap; Ryan Park; Zibo Li; Kai Chen; Lindsey Hughes; Aida Kouhi; Peter Conti
Journal:  Mol Imaging       Date:  2012 Sep-Oct       Impact factor: 4.488

3.  Magnetic resonance image-guided biopsies with a high detection rate of prostate cancer.

Authors:  Dirk G Engehausen; Karl Engelhard; Siegfried A Schwab; Michael Uder; Sven Wach; Bernd Wullich; F Steffen Krause
Journal:  ScientificWorldJournal       Date:  2012-03-12

4.  Touch imprint cytology of prostate core needle biopsy specimens: A useful method for immediate reporting of prostate cancer.

Authors:  Berna Aytac; Fatma Oz Atalay; Hakan Vuruskan; Gulaydan Filiz
Journal:  J Cytol       Date:  2012-07       Impact factor: 1.000

5.  Repeat prostate biopsy strategies after initial negative biopsy: meta-regression comparing cancer detection of transperineal, transrectal saturation and MRI guided biopsy.

Authors:  Adam W Nelson; Rebecca C Harvey; Richard A Parker; Christof Kastner; Andrew Doble; Vincent J Gnanapragasam
Journal:  PLoS One       Date:  2013-02-27       Impact factor: 3.240

6.  Low incidence of prostate cancer identified in the transition and anterior zones with transperineal biopsy.

Authors:  Teresa L Danforth; K Kent Chevli; Louis Baumann; Michael Duff
Journal:  Res Rep Urol       Date:  2012-12-05

7.  Transrectal ultrasound-guided prostate rebiopsy: How many core sampling should be applied to which patient?

Authors:  Akın Soner Amasyalı; Uğur Yücetaş; Erkan Erkan; Murat Demiray; Emre Karabay; Cemalettin Murat; Gökhan Toktaş; Erdinç Ünlüer
Journal:  Urol Ann       Date:  2018 Jan-Mar
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.